A complete, evidence-based guide to Apoquel (oclacitinib) — how it works, who qualifies, the exact FDA-approved dosing protocol, what the research actually says about cancer risk, and every important question your vet may not have had time to answer.
Apoquel has become one of the most prescribed veterinary medications in the United States since the FDA approved it in 2013, with more than a decade of real-world data now available on its safety profile. It works faster and with fewer gastrointestinal side effects than cyclosporine, and without the metabolic consequences of long-term steroids — but it is not without its own risks, considerations, and ongoing scientific questions. This guide gives you the honest, sourced picture that a vet who had 45 minutes for your appointment would want you to know.
-
1
What is Apoquel and what is it FDA-approved to treat in dogs? Apoquel (oclacitinib maleate) is an FDA-approved selective JAK1 inhibitor made by Zoetis. It was approved on May 14, 2013 specifically to control pruritus (itching) associated with allergic dermatitis and to control atopic dermatitis in dogs at least 12 months of age.Oclacitinib works by selectively inhibiting Janus kinase 1 (JAK1), a signaling enzyme that transmits the inflammatory messages causing itch — including the signal from IL-31, the cytokine most directly responsible for the sensation of pruritus in dogs. By blocking JAK1, Apoquel interrupts the itch signal before your dog’s brain registers it, providing relief that begins within 4 hours and is substantial by 24 hours. A chewable formulation (Apoquel Chewable) with pork-liver flavor was FDA-approved in 2023 to improve compliance for dogs requiring long-term therapy. Both formulations contain the same active ingredient; only the excipients differ.
-
2
What is the correct Apoquel dosage for dogs? The FDA-approved dose is 0.4 to 0.6 mg/kg body weight, given twice daily for up to 14 days (the loading phase), then once daily for long-term maintenance. The dose range is strict — going above it increases immune suppression without adding benefit, and going below it often fails to control symptoms.Per the FDA Freedom of Information Summary (the original approval document): the dose is 0.18 to 0.27 mg per pound (0.4 to 0.6 mg/kg), orally, twice daily for up to 14 days, then once daily thereafter. Apoquel is available in 3.6 mg, 5.6 mg, and 16 mg scored tablets. Each tablet is marked AQ and either S, M, or L. A board-certified veterinary dermatologist writing on PetDermatologyClinic.com states: “The dose range is very strict — I do not recommend going above the recommended dose due to immune suppression, below the range and it doesn’t seem to work in most cases.” The twice-daily phase is not FDA-approved beyond 14 days — continuing twice-daily dosing long-term is off-label use. Never use extended-release tablet formulations, which are not appropriate for dogs.
-
3
How quickly does Apoquel work and how long does the effect last? Apoquel begins reducing itch within 4 hours of the first dose. Most dogs experience significant relief within 24 hours. However, the antipruritic effect wears off within 12–24 hours, which is why daily dosing is required for continuous relief.This rapid onset and short duration is a defining characteristic of Apoquel that distinguishes it from cyclosporine (which takes 4–6 weeks to reach full effect) and makes it useful for both immediate itch control and long-term management. The short half-life also means that if you miss a dose, your dog’s itching may return quickly — but it also means that if you need to stop the medication (for example, due to infection), it clears the system relatively quickly. Zoetis reports that 60% of moderate-to-severe atopic dermatitis cases are well controlled long-term at once-daily dosing. Some severe cases do better with twice-daily dosing long-term, but this is off-label use.
-
4
Who should NOT take Apoquel? Apoquel is contraindicated in dogs under 12 months of age, dogs with serious infections (including bacterial, viral, fungal, or parasitic infections), and dogs with known hypersensitivity to oclacitinib. Extra caution is warranted in dogs with a history of cancer, dogs with pre-existing immune-mediated conditions, and pregnant or breeding animals.The FDA’s safety information states explicitly: “Do not use Apoquel in dogs less than 12 months of age or those with serious infections.” The reason for the age restriction is documented: in a margin-of-safety study on 6-month-old dogs given three to five times the regular dose, bacterial pneumonia and demodectic mange developed at unacceptable rates. Importantly, dogs with serious infections must have those infections treated and resolved before starting Apoquel, as immunosuppression during active infection can cause serious harm. A board-certified veterinary dermatologist (Dr. Diana M. Simões, DACVD) advises caution in dogs with severe secondary infections, untreated parasitic or fungal disease, and autoimmune disease. Dogs with a history of cancer require individualized risk-benefit discussion with your veterinarian.
-
5
What are the most common side effects of Apoquel? The most common side effects listed in the product insert are vomiting, diarrhea, lethargy, decreased appetite, and subcutaneous or dermal masses (skin lumps). Blood work changes can include decreased white blood cells (leukocytes), decreased globulins, and increased cholesterol and lipase. Most dogs tolerate Apoquel well with rare side effects at recommended doses.The 2025 pharmacovigilance review published in the Journal of Veterinary Pharmacology and Therapeutics (Nederveld et al., PMC/Wiley) confirms that in post-approval surveillance, the types and rank order of reported adverse events were similar to the pre-marketing field studies, with diarrhea, anorexia, and lethargy among the most frequently reported. A key finding from the surveillance data: adverse events were consistent with what was identified before approval — no new major safety signals emerged after over a decade of widespread use. Most adverse effects are mild and often transient. The risk of GI upset is notably lower with Apoquel than with cyclosporine. A veterinary dermatologist summarizes: “It is very rare to have GI upsets with Apoquel like we can see with cyclosporine.”
-
6
Does Apoquel cause cancer in dogs? What does the research actually say? The current evidence does not show that Apoquel causes cancer in dogs at recommended doses. A peer-reviewed age- and breed-matched study of 660 dogs found no meaningful difference in malignancy rates between oclacitinib-treated and untreated dogs. However, the FDA product label does warn that Apoquel may worsen pre-existing cancers, and regular cancer screening is recommended during long-term therapy.This is the most asked and most emotionally charged question about Apoquel, and it deserves a straight answer. A 2020 study published in the Journal of the American Veterinary Medical Association (JAVMA) compared 339 dogs treated long-term with oclacitinib to 321 age- and breed-matched dogs treated without it. Malignancy rates were 16.5% in the oclacitinib group versus 12.8% in the control group — a difference that was not statistically meaningful and not dose-dependent. The conclusion: “Long-term treatment with oclacitinib did not pose additional risk for malignancy in dogs.” However, the FDA label and multiple veterinary dermatologists emphasize that Apoquel can worsen pre-existing cancers (because JAK1 is involved in tumor surveillance), new neoplastic findings are listed on the label (including mast cell tumors and lymphomas), and regular screening for new skin masses is recommended during treatment. Dr. Karyn Wesley (University of Arizona CVM) states: “Studies show dogs using Apoquel haven’t shown any consistent increase in new cancer development when compared to control populations — I avoid this medication in dogs for whom cancer is a concern based on their history or my exam findings.”
-
7
What blood work monitoring does Apoquel require? A board-certified veterinary dermatologist recommends a CBC and chemistry panel before starting Apoquel, again at 3 months, and then annually thereafter. This is particularly important in senior dogs. Monitoring catches bone marrow suppression and other blood changes before they become clinically significant.Because Apoquel works through JAK signaling pathways that are also important to bone marrow function, periodic blood work monitoring is standard practice during long-term therapy. The product insert and multiple veterinary dermatologists align on this recommendation. What to look for: decreased white blood cells (leukocytes), decreased globulins, increased cholesterol, and increased lipase. None of these changes is common at the approved dose, but detecting them early is the point of monitoring. Always bring your dog’s full blood work history to vet appointments, especially if you are switching veterinarians. At the ASPCA Animal Poison Control Center, oclacitinib toxicosis is a tracked category — veterinarians should report adverse events both to Zoetis at 1-888-963-8471 and to the FDA at 1-888-FDA-VETS (1-888-332-8387).
-
8
How does Apoquel compare to Cytopoint and steroids? Apoquel is an oral daily pill that targets JAK1 signaling; Cytopoint is a monthly injectable antibody that targets IL-31 directly; steroids broadly suppress the immune system. All three control itch but through different mechanisms and with different risk profiles. Each has situations where it is preferred.Apoquel and Cytopoint both target the itch pathway more specifically than steroids, avoiding many of the well-known metabolic side effects of long-term steroid use (increased thirst/urination, weight gain, liver changes, Cushing’s disease risk). Cytopoint requires a monthly injection by a veterinarian; Apoquel is administered at home daily. For severe flares requiring rapid relief, Apoquel’s 4-hour onset is often preferred over waiting for Cytopoint’s effect. For dogs that struggle with daily pills, Cytopoint eliminates compliance concerns. For dogs who need very short-term itch control and cost is a factor, a brief course of steroids remains an option. A board-certified veterinary dermatologist (DACVD) is the most qualified professional to recommend the right combination or sequence of therapies for a dog with complex allergic disease.
-
9
Can Apoquel be given with other medications? Apoquel does not have significant documented interactions with NSAIDs, anti-infectives, parasiticides, antifungals, or allergen-specific immunotherapy at approved doses. However, caution is warranted when combining with other immunosuppressants such as steroids and cyclosporine, as long-term combined safety data is limited.Vetster confirms that oclacitinib does not appear to have significant drug interactions with many commonly used pet medications. However, a veterinary dermatologist advises using caution with “other drugs that may affect the bone marrow.” In humans, JAK inhibitors are not recommended with CYP3A4 inhibitors like ketoconazole; the clinical significance of this interaction in dogs is not well-established, but disclosure to your vet is important. Long-term studies of Apoquel combined with cyclosporine or chronic high-dose steroids have not been conducted, making that combination a clinical judgment call rather than an evidence-based protocol. Apoquel is currently made only by Zoetis — there are no FDA-approved generic versions available, as the patent has not expired at this publication’s writing.
-
10
Is Apoquel a cure for dog allergies or only symptom control? Apoquel controls symptoms — it does not cure allergies. Allergic and atopic dermatitis are lifelong conditions in most dogs. Apoquel provides excellent symptom management, but the underlying allergic disease continues, and most dogs require ongoing management including allergen identification, environmental controls, and often multimodal therapy.Vetster and multiple veterinary dermatologists are clear on this point: oclacitinib provides excellent symptom control but does not address the underlying cause of the allergy. A complete management plan for a dog with atopic dermatitis often includes identifying and avoiding allergens (flea prevention, food trials, environmental controls), treating secondary infections (yeast or bacterial skin infections) that prevent Apoquel from working optimally, bathing protocols with appropriate shampoos, allergen-specific immunotherapy (allergy shots or sublingual drops, which can reduce the underlying sensitivity over time), and Apoquel or Cytopoint for ongoing itch control. The most sophisticated and successful outcomes come from working with a board-certified veterinary dermatologist (DACVD) who can build the complete picture — not just manage itch with a single drug indefinitely.
Sources: FDA FOI Summary Apoquel approval May 14 2013 (0.4–0.6 mg/kg; twice daily ≤14 days; once daily maintenance; 3.6/5.4/16 mg tablets; AQ-S/M/L markings; Rx status; indication control pruritus allergic dermatitis/atopic dermatitis ≥12 months); PMC/JVPT Nederveld Krautmann Mitchell 2025 May (JAK1 selective inhibitor; FDA 2013 approval; chewable 2023 approval; post-approval PV diarrhea anorexia lethargy consistent with pre-marketing; Zoetis-funded; pharmacovigilance surveillance program; Zenrelia comparison); JAVMA/PubMed 2020 age-breed-matched cohort 660 dogs (16.5% vs 12.8% malignancy; no additional risk; dose-independent; regular screening recommended); ASPCA/VETgirl July 2025 oclacitinib toxicosis (JAK1 inhibitor; 0.4–0.6 mg/kg approved; off-label cats; report FDA 1-888-FDA-VETS; Lister Basile Wegenast JVECC April 2025); PetDermatologyClinic.com DACVD (0.4–0.6 mg/kg; strict dose range; 4–24 hour onset; 12–24 hour duration; 60% controlled once-daily; CBC/chemistry before/3mo/annual; bone marrow monitoring; steroids caution; ketoconazole; Zoetis 1-888-963-8471); AKC/Dr. Karyn Wesley UA + Dr. Diana Simões DACVD (cancer risk no consistent increase; avoid if cancer history; severe infections caution; DACVD preferred management; lab work before starting; trial/error combinations); GoodRx Aug 14 2025 (0.18–0.27 mg/lb = 0.4–0.6 mg/kg; skip missed dose do not double; cancer risk mast cell tumors lymphomas); Vetster Oct 24 2025 (3.6/5.6/16 mg US strengths; no significant drug interactions NSAIDs anti-infectives parasiticides antifungals immunotherapy; 5-year safety review match; chewable pork-liver not food allergy trial dogs; pre-existing cancer worsen); BestiePaws.com Nov 25 2025 (FDA expanded safety communication: serious infections bacterial pneumonia fungal; neoplastic findings mast cell tumors lymphomas; JAK-STAT tumor surveillance; FDA warning letter False/Misleading Risk Presentation); Zoetis package insert (twice-daily ≤14 days FDA approved; once-daily maintenance; do not use <12 months; serious infections contraindicated)
This chart reflects the FDA-approved dosing range (0.4–0.6 mg/kg). Your veterinarian’s specific prescription determines the correct dose for your dog. Apoquel is a prescription medication — never adjust the dose without veterinary guidance. The dose range is intentionally narrow; board-certified dermatologists warn that going above it increases immune suppression without benefit.
| Dog Weight | Daily Dose Range (mg) | Loading Phase (BID ≤14 days) | Tablet Size(s) Commonly Used |
|---|---|---|---|
| 6.6–9.9 lb (3–4.5 kg) | 1.4–2.7 mg/dose | Same dose twice daily | 3.6 mg (split) |
| 10–14.9 lb (4.5–6.8 kg) | 1.8–4.1 mg/dose | Same dose twice daily | 3.6 mg tablet |
| 15–19.9 lb (6.8–9.1 kg) | 2.7–5.5 mg/dose | Same dose twice daily | 3.6 mg or 5.6 mg tablet |
| 20–29.9 lb (9.1–13.6 kg) | 3.6–8.2 mg/dose | Same dose twice daily | 5.6 mg tablet |
| 30–44.9 lb (13.6–20.4 kg) | 5.5–12.2 mg/dose | Same dose twice daily | 5.6 mg or 16 mg (split) |
| 45–59.9 lb (20.4–27.3 kg) | 8.2–16.4 mg/dose | Same dose twice daily | 16 mg tablet (whole or split) |
| 60–89.9 lb (27.3–40.9 kg) | 10.9–24.5 mg/dose | Same dose twice daily | 16 mg tablet |
| 90–129.9 lb (40.9–59.1 kg) | 16.4–35.5 mg/dose | Same dose twice daily | 16 mg + 5.6 mg tablets |
| 130+ lb (59+ kg) | 23.6+ mg/dose | Same dose twice daily | Multiple 16 mg tablets as prescribed |
BID = twice daily. Loading phase: twice daily for up to 14 days (FDA-approved). Maintenance: once daily thereafter (FDA-approved). Continued twice-daily dosing beyond 14 days is off-label. Each tablet is scored and can be split in half. Chewable tablets (pork-liver flavor) are available — not appropriate for dogs on pork-exclusion food allergy trials or with known pork allergy. Always follow your veterinarian’s exact instructions.
Unlike many medications where the guiding principle is “lowest effective dose,” Apoquel’s therapeutic window is narrow from the other direction too. Board-certified veterinary dermatologists note that below the 0.4 mg/kg threshold, the drug often fails to control symptoms in most dogs. The goal is to stay within the 0.4–0.6 mg/kg range, monitor for effects, and add other therapies if needed — not to reduce Apoquel further than the evidence supports. The once-daily maintenance dose is already the lowest FDA-evaluated effective dose for long-term use.
Sources: FDA FOI Summary Apoquel (0.4–0.6 mg/kg BID ≤14 days then SID; tablet strengths 3.6/5.4/16 mg scored; AQ-S/M/L; 20 and 100 count bottles); Vetster Oct 2025 (US tablet strengths 3.6/5.6/16 mg; Canada 3.6/5.4/16 mg; scored for splitting; chewable pork liver not food allergy trial dogs); PetDermatologyClinic.com DACVD (strict dose range; below range doesn’t work most cases; above range immune suppression; off-label twice-daily beyond 14 days; 60% moderate-severe controlled once-daily)
No single option is best for every dog. This comparison reflects what board-certified veterinary dermatologists actually consider when choosing between options. Many dogs end up on combinations tailored to their specific needs.
- Apoquel does not cure allergies — it controls the itch symptom while the underlying allergic disease continues.
- Apoquel does not treat the cause of secondary infections — yeast and bacterial skin infections must be separately treated, as they can prevent Apoquel from working effectively.
- Apoquel does not replace allergen-specific immunotherapy (allergy shots), which is the only treatment that can reduce the underlying allergic sensitivity over time.
- Apoquel should not be continued during a serious active infection without veterinary guidance, as immune suppression can worsen the infection.
The association between Apoquel and cancer in dogs is the most discussed and most emotionally charged topic surrounding this medication. Here is what peer-reviewed research, the FDA, and board-certified veterinary specialists actually say.
A 2020 peer-reviewed study published in JAVMA compared 339 dogs treated long-term with oclacitinib to 321 age- and breed-matched dogs that received other treatments. Malignancy rate in the oclacitinib group: 16.5%. Malignancy rate in the non-oclacitinib group: 12.8%. This difference was not statistically significant and not dose-dependent. The authors concluded: “Long-term treatment with oclacitinib did not pose additional risk for malignancy in dogs.” This is the largest and most rigorous published comparison to date. Additionally, oclacitinib was not mutagenic or genotoxic in a standard battery of pre-approval tests, and there were no proliferative changes in a 90-day toxicity study.
- The FDA product label warns that Apoquel may worsen pre-existing cancers because JAK1 pathways are involved in tumor immune surveillance. This is a biologically sound concern — even if the drug does not cause new cancers, it may allow existing ones to progress undetected.
- The FDA safety communication lists neoplastic findings during long-term therapy, including mast cell tumors and lymphomas. These are listed as potential findings in treated dogs, though their causal relationship to the drug remains unproven.
- The 2025 PMC pharmacovigilance review (Nederveld et al.) notes that regular screening for new skin masses is recommended during long-term treatment — with or without Apoquel, given that allergic dogs tend to develop skin masses at higher rates than the general population.
Current peer-reviewed evidence does not show that Apoquel causes new cancers at the approved dose in dogs without pre-existing cancer. However, the drug’s mechanism of action (suppressing JAK1, which is involved in tumor immune surveillance) is a real and biologically meaningful consideration. The clinical consensus from board-certified veterinary dermatologists: Apoquel should be used with caution or avoided in dogs with a history of cancer; regular skin mass checks should accompany long-term therapy; and annual blood work monitoring is standard practice. The honest answer is that “no proven causal link” does not mean “zero concern” — and an informed conversation with your veterinarian before starting long-term Apoquel therapy is not optional.
Sources: JAVMA/PubMed 2020 Stegemann et al. age-breed-matched cohort 660 dogs (16.5% oclacitinib vs 12.8% non-exposed; not statistically meaningful; dose-independent; screen regularly; long-term oclacitinib did not pose additional risk for malignancy); PMC/JVPT 2025 Nederveld et al. (pharmacovigilance review; regular neoplasia screening recommended; oclacitinib not mutagenic/genotoxic pre-approval; no proliferative changes 90-day toxicity study; JAK1 tumor surveillance); BestiePaws.com Nov 2025 (FDA expanded safety communication: neoplastic findings mast cell tumors lymphomas; serious infections; JAK-STAT tumor surveillance mechanism; FDA warning letter history); Zoetis position statement neoplasia (not mutagenic genotoxic; no structural alerts carcinogenicity; label warning precaution statements observed); AKC/Dr. Karyn Wesley UA (no consistent increase new cancer vs controls; avoid if cancer concern; exam findings guide); Oncotect.co (limited anecdotal evidence; causal link elusive; vet-guided use with monitoring)
The most clinically significant real-world safety concern with Apoquel is increased susceptibility to infections — not cancer. Because Apoquel suppresses JAK1, it reduces the immune response that normally fights bacteria, fungi, parasites, and some viruses. Dogs on Apoquel are at higher risk for bacterial skin infections (pyoderma), yeast infections (Malassezia), demodectic mange (Demodex mite overgrowth), urinary tract infections, and in more serious cases, deeper skin infections or disseminated fungal disease. This risk is why treating any active serious infection before starting Apoquel is mandatory, and why keeping vaccines current and using reliable parasite prevention is especially important in dogs on long-term Apoquel therapy. If your dog develops signs of infection (fever, lethargy, wound that isn’t healing, unusual skin discharge), contact your veterinarian before the next scheduled appointment.
Sources: PetDermatologyClinic.com DACVD (60% moderate-severe controlled once-daily; twice-daily off-label beyond 14 days; infections yeast bacteria mites prevent Apoquel working; CBC/chemistry before/3mo/annual); FDA FOI Summary (BID ≤14 days approved; SID maintenance approved); BestiePaws.com Nov 2025 (serious infections FDA expanded safety: bacterial pneumonia deep skin infections disseminated fungal; infection risk mechanism JAK1 immune suppression); AKC/Dr. Wesley (infection susceptibility mites; lab work before starting; vaccines current parasite prevention); Vetster (pre-existing cancer rare worsen; secondary infections treat separately)
Apoquel is not approved and should not be used in dogs under 12 months of age. The reason is documented and serious: safety studies using three to five times the recommended dose in 6-month-old dogs revealed bacterial pneumonia and demodectic mange at rates considered unacceptable. Even at therapeutic doses, the developing immune system of a puppy may respond differently than that of an adult dog. For puppies with severe itching, your veterinarian has several appropriate options: a short course of steroids at anti-inflammatory doses, Cytopoint (lokivetmab, which has a different mechanism and does not have the same age restriction), careful investigation of the underlying cause (food allergy is more commonly identified in young dogs), and medicated shampoos for temporary relief. Contact a board-certified veterinary dermatologist (DACVD) for complex cases in young dogs — early accurate diagnosis significantly improves long-term outcomes.
Several factors can reduce Apoquel’s effectiveness over time, none of which reflect true pharmacological tolerance (the drug retains its potency chemically). The most common causes: secondary infections with yeast or bacteria that must be separately treated before Apoquel works as well as it should; development of new allergen sensitivities (dogs with atopic dermatitis often develop additional sensitivities over time); disease progression requiring a multimodal approach beyond single-drug therapy; and in some cases, cytokine adaptation where chronic suppression of one pathway triggers compensatory upregulation of others. If Apoquel is losing effectiveness, schedule a thorough re-evaluation with your vet or request a referral to a board-certified veterinary dermatologist. A skin cytology to check for secondary infection is often the first diagnostic step.
This requires an individualized risk-benefit discussion with a veterinarian who knows your dog’s complete cancer history, current status, and overall health. The answer is not a blanket yes or no. The concern: JAK1 signaling plays a role in tumor immune surveillance, meaning Apoquel’s mechanism of action could theoretically allow pre-existing cancer cells to evade immune detection more easily. Dr. Karyn Wesley (University of Arizona CVM) states: “I avoid this medication in dogs for whom cancer is a concern based on their history or my exam findings.” However, a dog who had a benign tumor removed years ago presents a very different situation from one currently in active cancer treatment. For dogs with cancer or cancer history, alternatives like Cytopoint (which does not suppress JAK pathways broadly) or targeted topical therapies may be preferable. A board-certified veterinary oncologist and dermatologist together offer the most informed guidance for these patients.
Apoquel can generally be stopped without a taper if discontinuation is needed. Unlike corticosteroids, which suppress the adrenal gland and can cause an Addisonian crisis if stopped abruptly after long-term use, Apoquel does not suppress the HPA axis. However, stopping Apoquel abruptly in a dog with severe atopic dermatitis will likely result in rapid return of intense itching, sometimes worse than before treatment began — a rebound phenomenon related to the underlying allergic disease, not to the drug itself. If you need to stop Apoquel because of a serious infection or planned surgery, your vet may bridge the gap with a short course of steroids at anti-inflammatory doses. Never stop or change Apoquel without discussing it with your veterinarian first, especially if your dog is also on other medications.
Contact your veterinarian or an emergency animal hospital immediately — or call ASPCA Animal Poison Control at (888) 426-4435 or Pet Poison Helpline at (855) 764-7661. Do not wait for symptoms to develop. In July 2025, VETgirl published an ASPCA Poison Control update raising awareness of reports of severe oclacitinib toxicosis in overdose situations. Per published toxicology (Lister, Basile, Wegenast, JVECC April 2025), overdose can cause immune suppression, gastrointestinal effects, skin changes, and enlarged lymph nodes beyond what occurs at therapeutic doses. Treatment is supportive and should be guided by veterinary professionals with access to poison control consultation. Store Apoquel (and all medications) completely out of reach of pets — the flavored chewable formulation is especially palatable and at particular risk of accidental ingestion.
As of the publication of this guide, there is no FDA-approved generic version of Apoquel (oclacitinib) available in the United States. Apoquel is currently manufactured exclusively by Zoetis. In September 2024, the FDA approved Zenrelia (ilunocitinib), a different JAK inhibitor with the same indication, made by Elanco — but this is a different drug (a non-selective JAK inhibitor), not a generic. The FDA issued a Dear Veterinarian letter about Zenrelia regarding important safety information, including a Boxed Warning related to vaccine safety and infection risk. Apoquel’s patent status has been discussed publicly; when and if generic oclacitinib becomes available, your veterinarian and pharmacist will be the most current source of information. Compounding pharmacies can sometimes offer lower-cost compounded oclacitinib — discuss with your vet whether a compounded formulation is appropriate and legally compliant for your situation.
Sources: FDA FOI Summary (BID ≤14 days; SID maintenance; ≥12 months only; 6-month-old study demodicosis pneumonia at 3x and 5x dose); PetDermatologyClinic.com DACVD (secondary infections prevent efficacy; rebound itch on stopping; steroids bridge; ketoconazole; don’t stop abruptly without vet; taper steroids not Apoquel); AKC/Dr. Wesley + Dr. Simões DACVD (cancer history avoid; Cytopoint alternative; DACVD referral; multimodal management); BestiePaws.com Nov 2025 (tachyphylaxis cytokine adaptation; new sensitizations; JAK-STAT; Cytopoint alternative cancer concern); ASPCA/VETgirl July 2025 (overdose toxicosis reports; Lister Basile Wegenast JVECC April 2025; immune suppression overdose; GI; lymph nodes; call ASPCA (888) 426-4435; chewable palatability risk accidental ingestion); PMC/JVPT 2025 (Zenrelia ilunocitinib FDA Sept 19 2024 approval same indication; non-selective JAK; Boxed Warning vaccines infections; Elanco; Apoquel Zoetis only FDA-approved oclacitinib); FDA Dear Veterinarian Letter Zenrelia (Boxed Warning; vaccine safety; infection risk; read full insert)
Apoquel requires a valid veterinary prescription in the United States. Use the buttons below to find your nearest veterinarian, a board-certified veterinary dermatologist for complex allergy cases, or a 24-hour emergency clinic.
- Step 1: Treat and resolve any active infections first. Yeast infections, bacterial skin infections, ear infections, and parasitic infestations must be addressed before starting Apoquel. Active serious infections are an explicit contraindication. Infections also prevent Apoquel from working as well as it should, so treating them first gives you an accurate assessment of the drug’s effectiveness.
- Step 2: Get baseline blood work (CBC and chemistry panel) before the first dose. This is particularly important for senior dogs and any dog with a prior health history. Your veterinarian needs a baseline to compare against future monitoring results. This is standard practice recommended by board-certified veterinary dermatologists.
- Step 3: Have an honest conversation about your dog’s cancer history. If your dog has ever had any type of cancer — benign or malignant — tell your vet before starting Apoquel. This changes the risk-benefit calculation and may lead to recommending Cytopoint or other alternatives instead.
- Step 4: Ensure vaccinations and parasite prevention are current. Because Apoquel moderately suppresses immune function, dogs on long-term therapy should be current on core vaccines and on reliable year-round parasite prevention (heartworm, flea, and tick). Discuss with your vet whether your dog’s vaccine schedule should be adjusted.
- Step 5: Store Apoquel securely — especially the chewable version. The pork-liver chewable formulation is palatable enough that dogs may actively seek it out. Store all Apoquel tablets completely out of reach. If your dog accidentally eats multiple tablets, call ASPCA Animal Poison Control at (888) 426-4435 immediately — do not wait for symptoms.
- New lumps, bumps, or skin masses that appear or grow rapidly • Swollen lymph nodes (lumps under the jaw, shoulders, behind knees)
- Signs of infection: fever, lethargy, wounds that aren’t healing, unusual skin discharge
- Respiratory symptoms: coughing, labored breathing, unusual fatigue with activity
- Gastrointestinal changes: persistent vomiting, diarrhea, significant decrease in appetite
- Signs of overdose (from accidental extra ingestion): severe lethargy, extreme GI upset, enlarged lymph nodes
ASPCA Animal Poison Control (overdose): (888) 426-4435 • Pet Poison Helpline: (855) 764-7661 • Zoetis adverse event reporting: 1-888-963-8471 • FDA adverse event reporting: 1-888-FDA-VETS (1-888-332-8387)
© BestiePaws.com — This guide is independently researched and written for educational purposes only. We have no financial relationship with Zoetis, Elanco, or any pharmaceutical manufacturer. Apoquel is a prescription medication requiring a valid veterinarian-client-patient relationship. All dosing information, contraindications, and clinical guidance are sourced from FDA approval documents, peer-reviewed veterinary literature, and board-certified veterinary specialists. This content does not constitute veterinary medical advice. Always consult a licensed veterinarian for diagnosis and treatment decisions.
Zoetis Apoquel information: zoetisus.com/apoquel • Zoetis adverse events: 1-888-963-8471 • FDA adverse events: 1-888-FDA-VETS (1-888-332-8387) • ASPCA Poison Control: (888) 426-4435 • Find a DACVD: acvd.org • Pet Poison Helpline: (855) 764-7661
Primary sources: FDA FOI Summary Apoquel NADA approval May 14 2013 (oclacitinib maleate; 0.4–0.6 mg/kg BID ≤14 days then SID; 3.6/5.4/16 mg scored tablets; AQ-S/M/L; Rx only; control pruritus allergic dermatitis/atopic dermatitis ≥12 months); PMC/JVPT 2025 May Nederveld Krautmann Mitchell (JAK1 selective inhibitor; FDA 2013 chewable 2023; PV surveillance adverse events consistent pre-marketing; diarrhea anorexia lethargy top reported; Zenrelia FDA Sept 2024; non-selective JAK; Boxed Warning; Zoetis funded); JAVMA/PubMed 2020 Stegemann et al. 660 dogs (16.5% vs 12.8% malignancy; not statistically meaningful; dose-independent; long-term oclacitinib no additional malignancy risk; screen regularly; not mutagenic genotoxic); VETgirl/ASPCA Poison Control July 2025 oclacitinib toxicosis update (severe toxicosis overdose reports; Lister Basile Wegenast JVECC April 20 2025; report Zoetis 1-888-963-8471 and FDA 1-888-FDA-VETS; ASPCA (888) 426-4435); PetDermatologyClinic.com board-certified veterinary dermatologist (0.4–0.6 mg/kg strict range; 4–24 hour onset; 12–24 hour duration; 60% moderate-severe controlled SID; secondary infections prevent efficacy; CBC/chemistry before/3mo/annual; bone marrow monitoring; ketoconazole caution; JAK-1/JAK-3 inhibition IL-31 pathway; Zoetis 1-888-963-8471); AKC Dr. Karyn Wesley University Arizona CVM + Dr. Diana Simões DACVD Dermatology Pet Care (cancer no consistent new cancer increase; avoid if cancer concern/history; DACVD referral; infection susceptibility mites; lab work before; trial/error combinations; bone marrow high doses); GoodRx Aug 14 2025 (0.18–0.27 mg/lb = 0.4–0.6 mg/kg; skip missed dose; cancer mast cell tumors lymphomas label warning); Vetster Oct 24 2025 (3.6/5.6/16 mg US; scored; chewable pork liver not food allergy trial; no significant interactions NSAIDs/anti-infectives/parasiticides/antifungals/immunotherapy; pre-existing cancer rare worsen; 5-year safety review match; Zoetis only maker); BestiePaws.com Nov 25 2025 (FDA expanded safety communication serious infections bacterial pneumonia fungal deep skin; neoplastic mast cell tumors lymphomas; JAK-STAT tumor surveillance mechanism; FDA warning letter False/Misleading Risk Presentation; tachyphylaxis cytokine adaptation; chewable overdose risk); Zoetis Apoquel position statement neoplasia (not mutagenic genotoxic; no structural carcinogenicity alerts; label warnings precautions; PV data long-term clarity); Oncotect.co (limited anecdotal cancer evidence; causal link elusive; monitoring essential; vet-guided use)
I had my Louie on Apoquel for years because he would not stop scratching and chewing himself. Started Louie on Natures Blend by Dr Marty and after a week decided to take him off of apoquel and it worked. He doesn’t have that bad itch anymore. I spend 92.00 on Dr Marty dog food that last me a month & a half compared to 85.00 a month on Apoquel. Louie is 25lbs and eats a hand full every day. Also doesn’t have bad breath anymore. I even buy freeze dried treats for him. I do though give him a small packet of Cesars filets in gravy every morning after his walk, a small breakfast which he loves.